Anti-D Immunoglobulin in First Trimester Pregnancy Loss: Summary of Recommendations

Key Shift in Practice (2022–2024)

Organization-by-Organization Recommendations

🔴 ACOG (2024) — Clinical Practice Update

"Although not routinely indicated, Rh testing and RhIg administration can be considered on an individual basis in the context of a shared decision-making discussion."

• Applicable to all patients < 12+0 weeks undergoing abortion or experiencing pregnancy loss (spontaneous or managed — aspiration or medication)
• Suggests forgoing routine Rh testing and RhIg prophylaxis at < 12 weeks
• Where RhD testing and RhIg are logistically and financially feasible and do not hinder access to care, offering both can be considered (SMFM 2024 nuance)

🔴 WHO (2022) — Abortion Care Guideline

Recommends AGAINST anti-D immunoglobulin administration for both medical and surgical abortion at < 12 weeks.

• Recommendation is against routine use based on negligible risk of sensitization
• Standard of care (antenatal prophylaxis at 28 and 34 weeks) still applies

🟡 NICE (2023) — NG126: Ectopic Pregnancy and Miscarriage

• OFFER anti-D Ig 250 IU (50 mcg) to all RhD-negative women who have a surgical procedure (uterine aspiration) for ectopic pregnancy or miscarriage
• DO NOT OFFER anti-D Ig to women who:
  • Receive solely medical management for ectopic pregnancy or miscarriage
  • Have a threatened miscarriage
  • Have a complete miscarriage
  • Have a pregnancy of unknown location

🔴 Society of Family Planning (SFP) — 2022

• Recommends against routine Rh testing and RhIg for abortion at < 12 weeks
• Evidence from prospective cohort data (n=506, mean GA ~7 weeks): 0% of participants had newly elevated fetal red blood cell counts above the sensitization threshold post-abortion (95% CI 0–0.59%)

🟡 SOGC (2024) — Guideline No. 448

• Routine blood group typing and antibody screening before 8 weeks is NOT recommended
• Rh status testing must be offered to all patients with unknown Rh status over 12 weeks LMP
• Anti-D immune globulin must be offered to Rh-negative patients over 12 weeks
• Below 12 weeks: patients and providers may forego Rh testing and anti-D — applies to both medication abortion and aspiration procedures
• Epidemiologic evidence: no increase in clinically significant anti-D perinatal antibodies in the Netherlands (no prophylaxis < 10 weeks) vs Canada (prophylaxis all first trimester)

🟡 SMFM (2024) — Society for Maternal-Fetal Medicine Statement

• Acknowledges existing guidelines are based on limited data that don't convincingly demonstrate safety of withholding RhIg
• In settings where RhD testing and RhIg are logistically and financially feasible and do not hinder access to abortion care: recommend offering both for spontaneous and induced abortion at < 12 weeks
• Emphasizes balancing alloimmunization prevention with individual- and population-level harms of restricted access

🔴 National Abortion Federation (2024)

• No evidence that providing anti-D Ig in early pregnancy prevents alloimmunization and poor outcomes in a subsequent pregnancy
• Anti-D prophylaxis is not required if anti-D is not available at time of abortion

🇬🇧 SHOT UK (2023) — UK Aide-Mémoire

• Anti-D Ig is not required for threatened miscarriage before 12 weeks, complete miscarriage, or medical management of miscarriage < 12 weeks
• Anti-D Ig 250 IU required if surgical management (aspiration/evacuation) is performed in RhD-negative women

Summary Table

Rationale for the Shift

1. Negligible FMH before 12 weeks: Prospective flow cytometry data shows 0% of patients undergoing first-trimester abortion had fetal RBC counts exceeding the sensitization threshold
2. Population-level safety data: Countries not administering Anti-D < 10–12 weeks show no higher rates of clinically significant alloimmunization
3. Access to care concerns: Mandatory Rh testing and Anti-D administration create barriers to abortion access, particularly in low-resource settings
4. Absence of rigorous trial data: The only RCT (1972) was underpowered; no convincing evidence of benefit at this gestational age

Practical Takeaways

• Surgical uterine evacuation remains the main indication where Anti-D should still be considered (NICE, SHOT UK) — surgical manipulation may theoretically increase FMH risk
• Medical/expectant management and threatened/complete miscarriage: Not an indication for Anti-D < 12 weeks per most guidelines
• Shared decision-making: Where Anti-D is available and not a barrier to care, it remains reasonable to offer (SMFM, ACOG)
• The 12-week threshold is consistent across all guidelines as the cutoff below which routine prophylaxis is not supported

Note: SMFM (PMID: 38417536) published a 2024 practice guideline taking a more conservative stance than ACOG, recommending Anti-D be offered when feasible. Clinicians should apply local guidelines and consider individual patient context.

RCOG & UK Guidance on Anti-D in First Trimester Pregnancy Loss — Comparison with International Guidelines

Current Status of RCOG Guidance

1. BSH (British Society for Haematology) Guideline — primary technical reference for anti-D use
2. NICE NG126 (2023) — for ectopic pregnancy and miscarriage
3. NICE NG140 (abortion care, updated via 2024 surveillance review)
4. RCOG Best Practice in Abortion Care (2022) — referenced alongside WHO and SFP by NICE
5. SHOT UK Aide-Mémoire (August 2023) — practical clinical summary

UK/RCOG Ecosystem Recommendations at a Glance

NICE NG126 — Ectopic Pregnancy and Miscarriage (2023)

NICE NG140 — Abortion Care (2019, surveillance reviewed 2024)

• Anti-D prophylaxis should be offered to RhD-negative women undergoing abortion after 10+0 weeks
• Consider for surgical abortion up to and including 10+0 weeks
• No prophylaxis recommended for medical abortion up to and including 10+0 weeks
• The 2024 NICE surveillance review found no new high-quality evidence to change these recommendations; however, NICE noted WHO (2022) and SFP (2022) guidelines and chose to cross-refer to WHO to align with international best practice
• The 10-week threshold (rather than 12 weeks) remains the UK surgical cutoff

SHOT UK Aide-Mémoire (August 2023)

BSH Guideline (current — replaces RCOG GTG 22)

• Focuses on overall anti-D use in pregnancy
• Supports NICE's framework: anti-D is indicated for sensitising events, but spontaneous early miscarriage < 12 weeks is not considered a high-risk sensitising event
• Routine antenatal prophylaxis at 28 and 34 weeks remains core recommendation

Head-to-Head Comparison: RCOG Ecosystem vs International Guidelines

Key Points of Difference: UK vs International

1. The Surgical Exception

2. Threshold Differences

• UK uses 10 weeks as its internal threshold for the surgical consideration (NICE NG140) and 12 weeks as the broader cutoff (NICE NG126 for miscarriage management, SHOT UK)
• Most international guidelines use 12 weeks as the universal cutoff

3. Threatened Miscarriage

• UK (NICE NG126, SHOT UK): Explicitly states Anti-D is not required for threatened miscarriage
• International guidelines are generally consistent with this — threatened miscarriage is low-risk

4. Evidence Basis

5. Access to Care Considerations

Summary

The UK framework (NICE/SHOT/BSH) occupies a middle ground: it has already removed Anti-D from threatened miscarriage, complete miscarriage, and medical management < 12 weeks — aligning with WHO/ACOG — but retains it for surgical procedures (ERPC/aspiration) at 250 IU, which distinguishes it from WHO, ACOG, SOGC, and most other bodies.

RCOG Green-top No. 22 is no longer active; current authoritative UK guidance comes from NICE NG126 (miscarriage), NICE NG140 (abortion care), and SHOT UK (practical aide-mémoire).